IL279246B1 - Compositions comprising menaquinone-7 (mk-7) and/or menaquinol for prophylaxis of calciphylaxis - Google Patents
Compositions comprising menaquinone-7 (mk-7) and/or menaquinol for prophylaxis of calciphylaxisInfo
- Publication number
- IL279246B1 IL279246B1 IL279246A IL27924620A IL279246B1 IL 279246 B1 IL279246 B1 IL 279246B1 IL 279246 A IL279246 A IL 279246A IL 27924620 A IL27924620 A IL 27924620A IL 279246 B1 IL279246 B1 IL 279246B1
- Authority
- IL
- Israel
- Prior art keywords
- menaquinol
- calciphylaxis
- menaquinone
- prophylaxis
- compositions
- Prior art date
Links
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 title 2
- 206010051714 Calciphylaxis Diseases 0.000 title 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 title 1
- CZHYZLLLSCZMRL-NTCAYCPXSA-N menaquinol Chemical compound C1=CC=CC2=C(O)C(C/C=C(C)/CCC=C(C)C)=C(C)C(O)=C21 CZHYZLLLSCZMRL-NTCAYCPXSA-N 0.000 title 1
- 235000009464 menaquinone-7 Nutrition 0.000 title 1
- 239000011700 menaquinone-7 Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682794P | 2018-06-08 | 2018-06-08 | |
| PCT/US2019/036139 WO2019237054A1 (en) | 2018-06-08 | 2019-06-07 | Methods and compositions for preventing or treating calciphylaxis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL279246A IL279246A (en) | 2021-01-31 |
| IL279246B1 true IL279246B1 (en) | 2023-04-01 |
| IL279246B2 IL279246B2 (en) | 2023-08-01 |
Family
ID=68763971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279246A IL279246B2 (en) | 2018-06-08 | 2020-12-06 | Compositions comprising menaquinone-7 (mk-7) and/or menaquinol for prophylaxis of calciphylaxis |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10736858B2 (en) |
| EP (1) | EP3801478A4 (en) |
| JP (1) | JP2021527129A (en) |
| KR (1) | KR20210018422A (en) |
| CN (1) | CN112955131A (en) |
| AU (1) | AU2019282421A1 (en) |
| CA (1) | CA3102979A1 (en) |
| IL (1) | IL279246B2 (en) |
| MX (1) | MX2020013301A (en) |
| SG (1) | SG11202012055PA (en) |
| WO (1) | WO2019237054A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210018422A (en) | 2018-06-08 | 2021-02-17 | 에피존 파마 인코포레이티드 | Method and composition for preventing or treating resistant calcium formation |
| IL279245B2 (en) | 2018-06-08 | 2024-03-01 | Epizon Pharma Inc | Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification |
| CA3111108A1 (en) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
| WO2020142687A1 (en) * | 2019-01-04 | 2020-07-09 | Kaydence Pharma As | Combination therapy of phosphate binders and vitamin k |
| CN112691058A (en) * | 2020-12-31 | 2021-04-23 | 玉溪健坤生物药业有限公司 | Reduced vitamin K-containing food2Toothpaste and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006607A2 (en) * | 2006-07-14 | 2008-01-17 | Nattopharma Asa | Pharmaceutical and nutraceutical products comprising vitamin k2 |
| WO2016131993A2 (en) * | 2015-02-20 | 2016-08-25 | Vitak B.V. | Vitamin k and capillary function |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176778A1 (en) | 2001-08-03 | 2005-08-11 | Vitak Bv | Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification |
| US20050123603A1 (en) | 2003-09-26 | 2005-06-09 | Natural Asa | Natural menaquinone 7 compositions |
| PL1728507T3 (en) | 2005-06-03 | 2011-09-30 | Nattopharma Asa | Use of vitamin K for reversing calcification of blood vessels |
| GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
| WO2012059942A2 (en) | 2010-11-01 | 2012-05-10 | Viridis Biopharma Pvt. Ltd | Dynamic balancing of autonomic nervous system through vitamin mk-7 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| US10159787B2 (en) | 2012-06-18 | 2018-12-25 | Fresenius Kabi Deutschland Gmbh | Port cannula system for puncturing port catheters |
| WO2014191466A1 (en) | 2013-05-28 | 2014-12-04 | Nattopharma Asa | Menaquinone supplementation and vascular health |
| GB201314245D0 (en) | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
| GEP20197040B (en) | 2015-03-20 | 2019-11-11 | Gnosis Spa | Solid forms of menaquinols |
| IT201700085412A1 (en) * | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composition for use in the prevention and treatment of cardiovascular diseases |
| US10368858B1 (en) | 2018-01-25 | 2019-08-06 | Ring Orthopedics, Inc. | Suture passer |
| KR20210018422A (en) | 2018-06-08 | 2021-02-17 | 에피존 파마 인코포레이티드 | Method and composition for preventing or treating resistant calcium formation |
| IL279245B2 (en) | 2018-06-08 | 2024-03-01 | Epizon Pharma Inc | Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification |
| CA3111108A1 (en) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
-
2019
- 2019-06-07 KR KR1020217000119A patent/KR20210018422A/en unknown
- 2019-06-07 JP JP2021518057A patent/JP2021527129A/en active Pending
- 2019-06-07 US US16/435,230 patent/US10736858B2/en active Active
- 2019-06-07 WO PCT/US2019/036139 patent/WO2019237054A1/en unknown
- 2019-06-07 CN CN201980052691.0A patent/CN112955131A/en active Pending
- 2019-06-07 SG SG11202012055PA patent/SG11202012055PA/en unknown
- 2019-06-07 CA CA3102979A patent/CA3102979A1/en active Pending
- 2019-06-07 EP EP19814419.8A patent/EP3801478A4/en active Pending
- 2019-06-07 MX MX2020013301A patent/MX2020013301A/en unknown
- 2019-06-07 AU AU2019282421A patent/AU2019282421A1/en active Pending
-
2020
- 2020-06-16 US US16/902,701 patent/US10925838B2/en active Active
- 2020-06-16 US US16/902,705 patent/US11065212B2/en active Active
- 2020-06-16 US US16/902,709 patent/US10987320B2/en active Active
- 2020-07-31 US US16/944,479 patent/US10940123B2/en active Active
- 2020-12-06 IL IL279246A patent/IL279246B2/en unknown
-
2021
- 2021-06-16 US US17/349,663 patent/US11793773B2/en active Active
-
2023
- 2023-08-07 US US18/231,035 patent/US20240041794A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006607A2 (en) * | 2006-07-14 | 2008-01-17 | Nattopharma Asa | Pharmaceutical and nutraceutical products comprising vitamin k2 |
| WO2016131993A2 (en) * | 2015-02-20 | 2016-08-25 | Vitak B.V. | Vitamin k and capillary function |
Non-Patent Citations (4)
| Title |
|---|
| CALUWE R ET AL.,, VITAMIN K2 SUPPLEMENTATION IN HAEMODIALYSIS PATIENTS: A RANDOMIZED DOSE-FINDING STUDY. NEPHROLOGY DIALYSIS TRANSPLANTATION, 30 July 2014 (2014-07-30) * |
| CHRISTIADI D SINGER RF,, CALCIPHYLAXIS IN A DIALYSIS PATIENT SUCCESSFULLY TREATED WITH HIGH-DOSE VITAMIN K SUPPLEMENTATION, 10 November 2017 (2017-11-10) * |
| KURNATOWSKA I ET AL.,, PLASMA DESPHOSPHO-UNCARBOXYLATED MATRIX GLA PROTEIN AS A MARKER OF KIDNEY DAMAGE AND CARDIOVASCULAR RISK IN ADVANCED STAGE OF CHRONIC KIDNEY DISEASE, 21 April 2016 (2016-04-21) * |
| SCHEIBER, D. ET AL.,, HIGH-DOSE MENAQUINONE-7 SUPPLEMENTATION REDUCES CARDIOVASCULAR CALCIFICATION IN A MURINE MODEL OF EXTRAOSSEOUS CALCIFICATION, 18 August 2015 (2015-08-18) * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020013301A (en) | 2021-05-12 |
| US20200306206A1 (en) | 2020-10-01 |
| US20200360301A1 (en) | 2020-11-19 |
| US10940123B2 (en) | 2021-03-09 |
| CN112955131A (en) | 2021-06-11 |
| EP3801478A4 (en) | 2022-02-23 |
| US20200306207A1 (en) | 2020-10-01 |
| US10736858B2 (en) | 2020-08-11 |
| CA3102979A1 (en) | 2019-12-12 |
| SG11202012055PA (en) | 2021-01-28 |
| US11065212B2 (en) | 2021-07-20 |
| US20210378987A1 (en) | 2021-12-09 |
| JP2021527129A (en) | 2021-10-11 |
| IL279246A (en) | 2021-01-31 |
| AU2019282421A1 (en) | 2021-01-07 |
| US20190374483A1 (en) | 2019-12-12 |
| US10925838B2 (en) | 2021-02-23 |
| US11793773B2 (en) | 2023-10-24 |
| KR20210018422A (en) | 2021-02-17 |
| US10987320B2 (en) | 2021-04-27 |
| EP3801478A1 (en) | 2021-04-14 |
| US20240041794A1 (en) | 2024-02-08 |
| IL279246B2 (en) | 2023-08-01 |
| US20200306208A1 (en) | 2020-10-01 |
| WO2019237054A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279246A (en) | Compositions comprising menaquinone-7 (mk-7) and/or menaquinol for prophylaxis of calciphylaxis | |
| IL279245A (en) | Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification | |
| EP3595653A4 (en) | Compositions of plinabulin and use thereof | |
| EP3463277A4 (en) | Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same | |
| EP3634426A4 (en) | Compositions for the treatment of fibrosis | |
| IL284628A (en) | Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile | |
| EP3426671A4 (en) | Compounds and compositions for the treatment of infections | |
| EP3661552A4 (en) | Compositions and methods for inhibition of mica/b shedding | |
| IL272857A (en) | Formulations of copanlisib | |
| EP3927868C0 (en) | Use of sulfidic compositions | |
| IL290324A (en) | Compositions of trofinetide | |
| EP3402463A4 (en) | Formulations of vancomycin | |
| ZA201907487B (en) | Compositions and treatment procedures for the treatment of pathogenic infections | |
| GB201911925D0 (en) | Formulations for prevention or reduction of c. difficile infections | |
| EP3687475A4 (en) | Stabilization of epinephrine formulations | |
| EP4041222A4 (en) | Cannabidiol-enhanced probiotic compositions and uses thereof for treatment of infections | |
| EP3719032A4 (en) | Composition for prevention or treatment of hair loss | |
| EP3463322A4 (en) | Methods and compositions for treatment of hypercalciuria and nephrolithiasis | |
| GB201913701D0 (en) | Composition of matter | |
| GB201919180D0 (en) | New composition of matter | |
| EP3846831A4 (en) | Combination probiotic compositions | |
| PT3678644T (en) | Formulations of copanlisib | |
| EP3648654A4 (en) | Synergistic compositions and devices for gynecological procedures | |
| EP3784261A4 (en) | Compositions and methods for prophylaxis or treatment of pain | |
| IL256675A (en) | Methods and compositions for prevention and treatment of pressure ulcers |